Business Update Neutral

2026-05-28 16:03

Cipla Limited informed about an upcoming in-person meeting with Citi India Conference scheduled for 5th June 2026 in Mumbai. The company noted that the schedule is subject to change due to unforeseen circumstances.

Business Update Positive

2026-05-15 18:35

Cipla management guided for North America to achieve a $1 billion run rate by the end of FY27 and expects strong double-digit growth in its India business for FY27-28. EBITDA margins are projected to be 18.5-20% for FY27, targeting over 20% in FY28, excluding Lanreotide's contribution for FY27. R&D spend will be sustained at 6-7% of revenue, focusing on complex products with 40-50 filings over three years, driving future growth. The company maintains a healthy net cash equivalent balance of INR 10,526 crores and is accelerating AI-led transformation.

Ownership Neutral

2026-05-14 12:12

Cipla Limited announced on May 14, 2026, the allotment of 17,915 fully paid-up equity shares of INR 2 each, following the exercise of employee stock options/stock appreciation rights under its ESOS 2013-A and ESAR 2021 schemes. Consequently, the company's issued, subscribed, and paid-up share capital increased to INR 1,61,56,01,092, comprising 80,78,00,546 equity shares of face value INR 2 each.

Business Update Neutral

2026-05-13 20:06

Cipla Ltd. announced the availability of the audio recording of its earnings conference call for the quarter and financial year ended March 31, 2026, which was held today. The recording is accessible on the company's website at https://www.cipla.com/audio/14837.

Governance Neutral

2026-05-13 13:24

Cipla's Board meeting on May 13, 2026, approved the 90th Annual General Meeting for June 25, 2026. The Board also approved the grant of employee stock options and Employee Stock Appreciation Rights (ESARs). M/s Joshi Apte & Associates was appointed as Cost Auditors for FY 2026-27. Additionally, Mr. Sushrut Kulkarni was appointed as President & Global Chief - Integrated Product Development and Senior Management Personnel, effective May 18, 2026.

Governance Positive

2026-05-13 13:18

Cipla's Board of Directors, at its meeting on May 13, 2026, approved the convening of the 90th Annual General Meeting on June 25, 2026. The board also approved the grant of employee stock options and appreciation rights. Furthermore, M/s Joshi Apte & Associates were appointed as Cost Auditors for FY 2026-27, and Mr Sushrut Kulkarni was appointed as President & Global Chief - Integrated Product Development, effective May 18, 2026.

Governance Positive

2026-05-13 13:14

Cipla's Board of Directors, meeting on May 13, 2026, approved the convening of its 90th Annual General Meeting on June 25, 2026. Key decisions included the grant of employee stock options and ESARs, the appointment of M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27, and the appointment of Mr. Sushrut Kulkarni as President & Global Chief - Integrated Product Development (IPD) and Senior Management Personnel, effective May 18, 2026.

Governance Positive

2026-05-13 13:09

Cipla's Board of Directors, at its meeting on May 13, 2026, approved the convening of the 90th Annual General Meeting on June 25, 2026. The board also approved the grant of employee stock options and appreciation rights (ESARs). M/s Joshi Apte & Associates were appointed as Cost Auditors for FY 2026-27. Additionally, Mr. Sushrut Kulkarni was appointed as President & Global Chief - Integrated Product Development, effective May 18, 2026, strengthening the management team.

Financials Negative

2026-05-13 13:00

Consolidated Revenue ₹6,541 Cr vs ₹6,730 Cr (▼2.8% YoY), EBITDA ₹997 Cr vs ₹1,538 Cr (▼35.2% YoY), PAT ₹555 Cr vs ₹1,222 Cr (▼54.6% YoY). EBITDA Margin 15.2% vs 22.8% (▼760bps).

Financials Negative

2026-05-13 12:46

Cipla reported Consolidated Revenue of ₹6,541.20 Cr vs ₹7,049.68 Cr (▼7.2% YoY), EBITDA of ₹1,050.89 Cr vs ₹1,855.85 Cr (▼43.4% YoY), and PAT of ₹550.11 Cr vs ₹1,225.02 Cr (▼55.1% YoY) for the quarter ended 31st March, 2026. EBITDA Margin contracted to 16.1% from 26.3% (▼1020bps). The Board also recommended a final dividend of INR 13/- per equity share for the financial year ended 31st March, 2026.

Financials Negative

2026-05-13 12:44

Consolidated Revenue ₹6,541.20Cr vs ₹6,729.69Cr (▼2.79% YoY), EBITDA ₹954.95Cr vs ₹1,537.59Cr (▼37.89% YoY), PAT ₹542.51Cr vs ₹1,214.14Cr (▼55.33% YoY). EBITDA Margin 14.60% vs 22.85% (▼825bps). The Board also recommended a final dividend of INR 13/- per equity share for the financial year ended 31st March, 2026.

Financials Negative

2026-05-13 12:38

Cipla announced consolidated financial results for the quarter ended 31st March 2026. Consolidated Revenue stood at ₹6,541.20 Cr versus ₹6,729.69 Cr in the prior year quarter (▼2.80% YoY). EBITDA was ₹954.95 Cr versus ₹1,537.59 Cr (▼37.89% YoY), and PAT was ₹542.51 Cr versus ₹1,214.14 Cr (▼55.33% YoY). EBITDA Margin contracted to 14.60% from 22.85% (▼825 bps). The Board also recommended a final dividend of INR 13/- per equity share for the financial year ended 31st March 2026.

Business Update Positive

2026-04-23 09:48

Cipla received U.S. FDA final approval for the first AB-rated generic of Ventolin® HFA (Albuterol Sulfate Inhalation Aerosol), targeting the estimated $1.5 billion U.S. albuterol market. The product is expected to be launched in H1 of FY 2026-27 in the United States.

Business Update Negative

2026-04-17 16:34

CRITICAL RED FLAG DETECTED

Cipla announced a USFDA inspection at its Goa manufacturing facility from April 6-17, 2026. The routine cGMP and PAI concluded with two (2) inspectional observations in Form 483, which the company is committed to addressing comprehensively.

Routine Neutral

2026-04-16 19:54

New Filing detected. See link for details.

Routine Neutral

2026-04-09 17:59

Cipla Limited filed a compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026, confirming timely processing of dematerialization requests by its Registrar and Share Transfer Agent, KFin Technologies Limited.

Governance Negative

2026-03-30 18:23

CRITICAL RED FLAG DETECTED

Mr. Umang Vohra resigned as Director and MD & CEO effective April 1, 2026, upon completing his term. Mr. Achin Gupta assumed charge as MD & Global CEO. Additionally, Mr. Saurabh Gambhir and Mr. Satyavan Manikani were categorized as Senior Management Personnel, also effective April 1, 2026.

Governance Negative

2026-03-30 18:20

CRITICAL RED FLAG DETECTED

Mr. Achin Gupta takes charge as Cipla's Managing Director and Global CEO. Mr. Saurabh Gambhir and Mr. Satyavan Manikani are appointed as Senior Management Personnel (SMPs) from April 1, 2026. Mr. Umang Vohra resigned as a Director, effective April 1, 2026, upon completion of his term as MD & Global CEO.

Governance Neutral

2026-03-26 22:15

Cipla Limited announced the results of its Postal Ballot. Members approved the appointment and remuneration of Mr. Achin Gupta as Director, Managing Director, and Global CEO, and the re-appointment of Mr. P.R. Ramesh as an Independent Director. All resolutions were passed with requisite majority.

Governance Negative

2026-03-26 20:39

CRITICAL RED FLAG DETECTED

Mr Pradeep Bhadauria, Global Chief Scientific Officer and member of the Management Council, has resigned from Cipla to pursue external interests. His last working day will be 31st March, 2026.

Governance Negative

2026-03-19 17:34

CRITICAL RED FLAG DETECTED

Cipla's Board approved a USD 100 million investment in Cipla (EU) for InvaGen's capital and working needs, and the amalgamation of Inzpera Healthsciences. Mr P R Ramesh was designated Vice-Chairman. Mr Robert Stewart will not seek re-appointment as an Independent Director upon completion of his term on 13th May 2026.

Governance Negative

2026-03-19 17:30

CRITICAL RED FLAG DETECTED

Cipla's Board meeting on March 19, 2026, appointed Mr. P R Ramesh as Lead Independent Director & Vice-Chairman, and Mr. Robert Stewart opted not to seek re-appointment as an Independent Director. The board also approved a USD 100 million investment in Cipla (EU) Limited and the amalgamation of Inzpera Healthsciences Limited.

Ownership Positive

2026-03-18 19:31

Cipla allotted 1,954 equity shares under its ESOS 2013-A and ESAR 2021 schemes on March 18, 2026. This allotment of fully paid-up shares of ₹2 each results in an increased paid-up share capital comprising 80,77,82,631 equity shares.

Business Update Negative

2026-03-09 22:52

Cipla USA Inc., a wholly owned subsidiary, initiated a recall of unexpired batches of Lanreotide Injection, leading to a temporary lack of supply to the market, as disclosed on March 9, 2026.

Business Update Positive

2026-03-02 20:07

Cipla Limited announced a 60:40 joint venture with Kemwell Biopharma Private Limited on March 2, 2026, to develop, manufacture, and commercialize biologic products in India for global markets. The initial investment will be up to INR 10 crores.

Business Update Positive

2026-03-02 19:30

Cipla Ltd. announced the incorporation of a new wholly-owned step-down subsidiary, 'Cipla Middle East Company', in Saudi Arabia on March 1, 2026. This entity aims to establish manufacturing and distribution of pharmaceutical products and hold marketing authorizations in KSA.

Business Update Negative

2026-02-26 17:21

CRITICAL RED FLAG DETECTED

Cipla's ESG rating for FY 2024-25 was revised downwards from 66 to 65 by NSE Sustainability. This revision is potentially due to a product recall by Cipla USA Inc., a subsidiary, in January 2026.

Governance Positive

2026-02-23 20:48

Cipla Ltd. issued a Notice of Postal Ballot dated 23rd January 2026 for shareholder approval. Resolutions include appointing Mr. Achin Gupta as Director, MD & GCEO, and approving his remuneration for 5 years. Also, re-appointing Mr. P R Ramesh as an Independent Director for 5 years.

Business Update Negative

2026-02-21 17:53

CRITICAL RED FLAG DETECTED

Cipla announced that the USFDA has classified the cGMP inspection at its supply partner Pharmathen International S.A.'s Rodopi, Greece facility as Official Action Indicated (OAI).

Business Update Neutral

2026-02-17 19:25

Cipla Limited intimated an in-person Analyst / Institutional Investor Meeting with Kotak Securities Conference on 23rd February 2026 in Mumbai, as per Regulation 30 of SEBI LODR Regulations.

Business Update Negative

2026-02-10 08:42

CRITICAL RED FLAG DETECTED

Cipla's subsidiary InvaGen received 2 USFDA Form 483 observations after a Pre-Approval Inspection (PAI) at its Hauppauge, New York manufacturing facility from Feb 2-9, 2026. The company committed to address the observations comprehensively.

Business Update Neutral

2026-02-08 14:51

Cipla announced that the Goods & Service Tax Department, Maharashtra, concluded an inspection/search on February 7, 2026. The company stated that no official document has been issued and there is no material impact on its financials or operations.

Business Update Negative

2026-02-05 23:34

CRITICAL RED FLAG DETECTED

Cipla disclosed that the Goods & Service Tax Department initiated inspection/search proceedings at its Maharashtra facilities on Feb 5, 2026, related to tax payments and input tax credit. The company is cooperating and states no financial or operational impact.

CIPLA

Cipla Limited

Filing History

Unlock Full History